Quantitative Systematic Strategies LLC Acquires 1,803 Shares of Thermo Fisher Scientific Inc (TMO)
Quantitative Systematic Strategies LLC raised its position in Thermo Fisher Scientific Inc (NYSE:TMO) by 47.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,580 shares of the medical research company’s stock after buying an additional 1,803 shares during the period. Quantitative Systematic Strategies LLC’s holdings in Thermo Fisher Scientific were worth $970,000 at the end of the most recent quarter.
Several other institutional investors have also bought and sold shares of TMO. BlackRock Inc. increased its position in Thermo Fisher Scientific by 2,692.1% in the first quarter. BlackRock Inc. now owns 22,988,885 shares of the medical research company’s stock worth $3,531,095,000 after buying an additional 22,165,530 shares in the last quarter. C WorldWide Group Holding A S increased its position in Thermo Fisher Scientific by 997.1% in the first quarter. C WorldWide Group Holding A S now owns 1,950,049 shares of the medical research company’s stock worth $299,527,000 after buying an additional 1,772,300 shares in the last quarter. Veritas Asset Management LLP acquired a new position in Thermo Fisher Scientific during the first quarter worth approximately $175,795,000. Vanguard Group Inc. increased its position in Thermo Fisher Scientific by 2.7% in the first quarter. Vanguard Group Inc. now owns 25,971,301 shares of the medical research company’s stock worth $3,989,193,000 after buying an additional 695,079 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in Thermo Fisher Scientific by 68.8% in the first quarter. Renaissance Technologies LLC now owns 1,373,044 shares of the medical research company’s stock worth $210,900,000 after buying an additional 559,400 shares in the last quarter. Institutional investors own 87.15% of the company’s stock.
Shares of Thermo Fisher Scientific Inc (NYSE TMO) traded up 1.15% during midday trading on Friday, reaching $173.71. 652,233 shares of the company’s stock traded hands. Thermo Fisher Scientific Inc has a 12 month low of $139.07 and a 12 month high of $182.87. The stock has a 50-day moving average price of $176.85 and a 200 day moving average price of $165.24. The firm has a market cap of $67.77 billion, a PE ratio of 30.26 and a beta of 1.06.
Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.27 by $0.03. The firm had revenue of $5 billion for the quarter, compared to analysts’ expectations of $4.92 billion. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The company’s quarterly revenue was up 10.2% on a year-over-year basis. During the same period in the previous year, the company earned $2.03 earnings per share. Equities research analysts predict that Thermo Fisher Scientific Inc will post $9.24 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Monday, October 16th. Shareholders of record on Friday, September 15th will be paid a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 0.35%. The ex-dividend date is Thursday, September 14th. Thermo Fisher Scientific’s payout ratio is 10.45%.
COPYRIGHT VIOLATION NOTICE: This news story was published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.watchlistnews.com/quantitative-systematic-strategies-llc-acquires-1803-shares-of-thermo-fisher-scientific-inc-tmo/1474319.html.
TMO has been the subject of a number of recent research reports. Morgan Stanley increased their price objective on shares of Thermo Fisher Scientific from $186.00 to $192.00 and gave the stock an “overweight” rating in a research note on Friday, April 28th. Deutsche Bank AG increased their price objective on shares of Thermo Fisher Scientific from $163.00 to $188.00 and gave the stock a “buy” rating in a research note on Friday, April 28th. Barclays PLC restated an “overweight” rating and set a $190.00 price objective (up from $175.00) on shares of Thermo Fisher Scientific in a research note on Tuesday, May 9th. Leerink Swann set a $187.00 price objective on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Thursday, April 27th. Finally, Cowen and Company restated an “outperform” rating and set a $185.00 price objective (up from $175.00) on shares of Thermo Fisher Scientific in a research note on Saturday, April 29th. One analyst has rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. Thermo Fisher Scientific currently has a consensus rating of “Buy” and a consensus target price of $188.56.
In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 2,500 shares of the business’s stock in a transaction dated Monday, June 5th. The shares were sold at an average price of $176.26, for a total value of $440,650.00. Following the transaction, the chief financial officer now directly owns 37,790 shares in the company, valued at $6,660,865.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Daniel P. Shine sold 4,688 shares of the business’s stock in a transaction dated Wednesday, May 24th. The shares were sold at an average price of $171.88, for a total transaction of $805,773.44. Following the completion of the transaction, the insider now owns 29,200 shares in the company, valued at $5,018,896. The disclosure for this sale can be found here. Over the last quarter, insiders sold 27,188 shares of company stock worth $4,702,223. Corporate insiders own 0.49% of the company’s stock.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.